Clinical trial of Osteoset-T in the treatment of elderly patients with chronic osteomyelitis
10.13699/j.cnki.1001-6821.2017.11.005
- VernacularTitle:负载妥布霉素的硫酸钙治疗老年慢性骨髓炎的临床研究
- Author:
Ning LU
1
;
Chun ZHANG
;
Zhan ZHANG
Author Information
1. 浙江省立同德医院骨科
- Keywords:
Osteoset-T;
chronic osteomyelitis;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(11):977-979
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of Osteoset-T in the treatment of elderly patients with chronic osteomyelitis.Methods A total of 58 elderly patients with chronic osteomyelitis were randomly divided into control group and treatment group with 26 cases per group.Two groups were treated with debridement.After debridement,control group was given gentamicin bone cement (4 mg · g-1) filling the cavity,the treatment group was given Osteoset-T (4％ Tobramycin)filling the cavity.The clinical efficacy,lysozyme (LZM),C reactive protein (CRP) and adverse drug reactions were compared between the two groups.Results After treatment,the total effective rates in treatment and control groups were 88.46％ (23/26 cases) and 65.38％ (17/26 cases) with significant difference (P ＜ 0.05).After treatment,LZM in treatment and control groups were (22.45 ± 1.78),(18.54 ±1.32) μg · L-1;CRP in treatment and control groups were (1.58 ± 0.22),(3.86 ± 0.43) mg · L-1,with significant differences (P ＜ 0.05).The adverse drug reactions in treatment group were local infiltration fluid,which in control group were local infiltration fluid and delayed wound healing.The incidences of adverse drug reactions in treatment and control groups were 3.85％ and 7.69％ without significant difference (P ＞0.05).Conclusion Osteoset-T has a definitive clinical efficacy in the treatment of elderly patients with chronic osteomyelitis,which can improve the levels of LZM,reduce the levels of CRP,without increasing the incidence of adverse drug reactions.
